137 related articles for article (PubMed ID: 23810190)
1. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells.
Jinushi M; Yagita H; Yoshiyama H; Tahara H
Trends Mol Med; 2013 Sep; 19(9):536-45. PubMed ID: 23810190
[TBL] [Abstract][Full Text] [Related]
2. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.
Hannani D; Sistigu A; Kepp O; Galluzzi L; Kroemer G; Zitvogel L
Cancer J; 2011; 17(5):351-8. PubMed ID: 21952286
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
Tadmor T; Attias D; Polliack A
Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
Kepp O; Galluzzi L; Martins I; Schlemmer F; Adjemian S; Michaud M; Sukkurwala AQ; Menger L; Zitvogel L; Kroemer G
Cancer Metastasis Rev; 2011 Mar; 30(1):61-9. PubMed ID: 21249425
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Zitvogel L; Galluzzi L; Smyth MJ; Kroemer G
Immunity; 2013 Jul; 39(1):74-88. PubMed ID: 23890065
[TBL] [Abstract][Full Text] [Related]
6. The inducers of immunogenic cell death for tumor immunotherapy.
Li X
Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
[TBL] [Abstract][Full Text] [Related]
7. Innate immunity and cancer therapy.
Maruyama K; Selmani Z; Ishii H; Yamaguchi K
Int Immunopharmacol; 2011 Mar; 11(3):350-7. PubMed ID: 20955832
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.
Garg AD; Romano E; Rufo N; Agostinis P
Cell Death Differ; 2016 Jun; 23(6):938-51. PubMed ID: 26891691
[TBL] [Abstract][Full Text] [Related]
9. Myeloid cells in sensing of tissue damage.
Del Fresno C; Sancho D
Curr Opin Immunol; 2021 Feb; 68():34-40. PubMed ID: 33035713
[TBL] [Abstract][Full Text] [Related]
10. Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies.
You L; Jin S; Zhu L; Qian W
Oncotarget; 2017 Feb; 8(7):12374-12388. PubMed ID: 27902471
[TBL] [Abstract][Full Text] [Related]
11. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.
Younos IH; Abe F; Talmadge JE
Leuk Lymphoma; 2015; 56(8):2251-63. PubMed ID: 25407654
[TBL] [Abstract][Full Text] [Related]
13. Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy.
Radogna F; Diederich M
Biochem Pharmacol; 2018 Jul; 153():12-23. PubMed ID: 29438676
[TBL] [Abstract][Full Text] [Related]
14. C-type lectin-like receptors on myeloid cells.
Pyz E; Marshall AS; Gordon S; Brown GD
Ann Med; 2006; 38(4):242-51. PubMed ID: 16754255
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
16. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.
Naiditch H; Shurin MR; Shurin GV
Immunol Res; 2011 Aug; 50(2-3):276-85. PubMed ID: 21717082
[TBL] [Abstract][Full Text] [Related]
18. Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Zdrenghea MT
Med Hypotheses; 2013 Aug; 81(2):311-5. PubMed ID: 23669372
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.
Aymeric L; Apetoh L; Ghiringhelli F; Tesniere A; Martins I; Kroemer G; Smyth MJ; Zitvogel L
Cancer Res; 2010 Feb; 70(3):855-8. PubMed ID: 20086177
[TBL] [Abstract][Full Text] [Related]
20. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
Allavena P; Sica A; Garlanda C; Mantovani A
Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]